

はなかなか進展がみられていない。最近、神経堤細胞の異常によって発症する先天性の致死性疾患である家族性自律神経失調症 (familial dysautonomia : FD) の疾患特異的 iPS 細胞を用いた HTS 解析が報告された⁵²⁾。Lee らは、以前に報告した FD 患者由来 iPS 細胞を神経堤細胞に分化させる方法⁵³⁾を用いて、原因遺伝子である IKBKAP の正常スプライシング産物が増加する化合物をスクリーニングしたところ、6,912 種類の化合物のうち 8 個の化合物が有効であった、と報告している。Lee らは、これらの化合物の効果は他の細胞種 (iPS 細胞、線維芽細胞やリンパ球) では十分認められなかったことから、疾患に関連する細胞種を分化させてスクリーニングすることの重要性を強調している。

疾患特異的 iPS 細胞の課題

疾患特異的 iPS 細胞には多くの可能性があるが、前述のように、現状では多くの疾患特異的 iPS 細胞の報告は“疾患モデリング”に留まっている。iPS 細胞技術を用いて、疾患の病態生理を深く解析するためには、解決すべき課題が存在する。最初の問題は、ある患者から樹立した複数 iPS 細胞クローンについて、クローン間表現型のばらつきが存在しうることであり、これが大きいと疾患に関連した真の表現型の解析が困難になる。このようなクローン間のばらつきは、ゲノム変異⁵⁴⁾、エピジェネティック修飾⁵⁵⁾、ソースとなる体細胞の種類、残存トランスジーン活性、および女性由来の細胞では X 染色体不活化状態がクローンによって異なること^{56)~58)} などにより生じる。さらに、いくつかの疾患、特に Fanconi 貧血などの DNA 修復異常症などでは iPS 細胞の樹立自体が難しいことがある。このような場合は、一旦遺伝子修復を行って iPS 細胞を樹立し、その後導入遺伝子を除去するなど、特殊な方法が必要になるかもしれない。

また、前述の通り、疾患特異的 iPS 細胞の対照群をどのようにとるか、ということも問題である。原因遺伝子が判明している場合、患者由来 iPS 細胞の原因遺伝子を修復して対照クローンとすれば、ゲノムバックグラウンドの差異による表現型のばらつきなどを最小限に抑えて解析することができる。ヒト多能性幹細胞の相同組み換え効率は極めて低かったが、最近、ヘルパー依存性アデノウイルスを用いる手法⁵⁹⁾や、Zinc finger nuclease⁶⁰⁾や TALEN⁶¹⁾といった配列特異的ヌクレアーゼを用いる方法により高効率かつ簡便に遺伝子ターゲティングが行えるようになってきた。今後はこのような手法を用いて、十分に機能評価がされた“正常” iPS 細胞クローンや ES 細胞に疾患特異的変異を導入し、疾患モデルして用いることも可能になると思われる⁶²⁾⁶³⁾。この場合、① iPS 細胞クローンの評価に時間と労力を割く必要がない、② 臨床研究に関する研究計画書を整備し、患者から同意を取得するという手順が省略できる、③ 分化能・分化した細胞の機能などが十

分に解析されたクローンを使用できる、といった利点があるため、単一遺伝子疾患の解析にはこちらが主流となっていくかもしれない。

三三三 終わりに

以上のように、課題もあるものの、疾患iPS細胞を用いることにより、疾患の表現型の少なくとも一部は試験管内で再現可能であることが次々と証明されている。iPS細胞を用いた治療薬開発や病態解明が進み、これまで治療法がなかったさまざまな難治性疾患に対するアプローチが少しでも早く進展することを期待したい。

■■■ 文献

- 1) Takahashi K, Yamanaka S : Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* **126** : 663-676, 2006
- 2) Takahashi K, Tanabe K, Ohnuki M, et al : Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell* **131** : 861-872, 2007
- 3) Rajesh D, Dickerson SJ, Yu J, et al : Human lymphoblastoid B-cell lines reprogrammed to EBV-free induced pluripotent stem cells. *Blood* **118** : 1797-1800, 2011
- 4) Choi SM, Liu H, Chaudhari P, et al : Reprogramming of EBV-immortalized B-lymphocyte cell lines into induced pluripotent stem cells. *Blood* **118** : 1801-1805, 2011
- 5) Sommer AG, Rozelle SS, Sullivan S, et al : Generation of human induced pluripotent stem cells from peripheral blood using the STEMCCA lentiviral vector. *J Vis Exp* 2012 Oct 31 ;(68), pii : 4327. doi : 10.3791/4327
- 6) Nishimura K, Sano M, Ohtaka M, et al : Development of defective and persistent Sendai virus vector: a unique gene delivery/expression system ideal for cell reprogramming. *J Biol Chem* **286** : 4760-4771, 2011
- 7) Fusaki N, Ban H, Nishiyama A, et al : Efficient induction of transgene-free human pluripotent stem cells using a vector based on Sendai virus, an RNA virus that does not integrate into the host genome. *Proc Jpn Acad Ser B Phys Biol Sci* **85** : 348-362, 2009
- 8) Okita K, Matsumura Y, Sato Y, et al : A more efficient method to generate integration-free human iPS cells. *Nat Methods* **8** : 409-412, 2011
- 9) Okita K, Yamakawa T, Matsumura Y, et al : An Efficient Non-viral Method to Generate Integration-Free Human iPS Cells from Cord Blood and Peripheral Blood Cells. *Stem Cells* 2012 Nov 29. doi : 10.1002/stem.1293 (Epub ahead of print)
- 10) Tanaka T, Takahashi K, Yamane M, et al : Induced pluripotent stem cells from CINCA syndrome patients as a model for dissecting somatic mosaicism and drug discovery. *Blood* **120** : 1299-1308, 2012
- 11) Cheung AY, Horvath LM, Grafodatskaya D, et al : Isolation of MECP2-null Rett Syndrome patient hiPS cells and isogenic controls through X-chromosome inactivation. *Hum Mol Genet* **20** : 2103-2115, 2011
- 12) Ebert AD, Yu J, Rose FF Jr, et al : Induced pluripotent stem cells from a spinal mus-

- cular atrophy patient. *Nature* **457** : 277-280, 2009
- 13) Chang T, Zheng W, Tsark W, et al : Brief report : phenotypic rescue of induced pluripotent stem cell-derived motoneurons of a spinal muscular atrophy patient. *Stem Cells* **29** : 2090-2093, 2011
 - 14) Corti S, Nizzardo M, Simone C, et al : Genetic correction of human induced pluripotent stem cells from patients with spinal muscular atrophy. *Sci Transl Med* **4** : 165ra162, 2012
 - 15) Egawa N, Kitaoka S, Tsukita K, et al : Drug screening for ALS using patient-specific induced pluripotent stem cells. *Sci Transl Med* **4** : 145ra104, 2012
 - 16) Bilican B, Serio A, Barmada SJ, et al : Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. *Proc Natl Acad Sci U S A* **109** : 5803-5808, 2012
 - 17) Marchetto MC, Carron ME, Acab A, et al : A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. *Cell* **143** : 527-539, 2010
 - 18) Muotri AR, Marchetto MC, Coufal NG, et al : L1 retrotransposition in neurons is modulated by MeCP2. *Nature* **468** : 443-446, 2010
 - 19) Israel MA, Yuan SH, Bardy C, et al : Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. *Nature* **482** : 216-220, 2012
 - 20) Qiang L, Fujita R, Yamashita T, et al : Directed conversion of Alzheimer's disease patient skin fibroblasts into functional neurons. *Cell* **146** : 359-371, 2011
 - 21) Soldner F, Hockemeyer D, Beard C, et al : Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. *Cell* **136** : 964-977, 2009
 - 22) Devine MJ, Ryten M, Vodicka P, et al : Parkinson's disease induced pluripotent stem cells with triplication of the alpha-synuclein locus. *Nat Commun* **2** : 440, 2011
 - 23) Byers B, Cord B, Nguyen HN, et al : SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate alpha-synuclein and are susceptible to oxidative stress. *PLoS One* **6** : e26159, 2011
 - 24) Nguyen HN, Byers B, Cord B, et al : LRRK2 mutant iPSC-derived DA neurons demonstrate increased susceptibility to oxidative stress. *Cell Stem Cell* **8** : 267-280, 2011
 - 25) Seibler P, Graziotto J, Jeong H, et al : Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells. *J Neurosci* **31** : 5970-5976, 2011
 - 26) Jiang H, Ren Y, Yuen EY, et al : Parkin controls dopamine utilization in human mid-brain dopaminergic neurons derived from induced pluripotent stem cells. *Nat Commun* **3** : 668, 2012
 - 27) Cooper O, Seo H, Andrabi S, et al : Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson's disease. *Sci Transl Med* **4** : 141ra90, 2012
 - 28) Brennand KJ, Simone A, Jou J, et al : Modelling schizophrenia using human induced pluripotent stem cells. *Nature* **473** : 221-225, 2011
 - 29) Yazawa M, Hsueh B, Jia X, et al : Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. *Nature* **471** : 230-234, 2011
 - 30) Pasca SP, Portmann T, Voineagu I, et al : Using iPSC-derived neurons to uncover cel-

- lular phenotypes associated with Timothy syndrome. *Nat Med* **17** : 1657-1662, 2011
- 31) Moretti A, Bellin M, Welling A, et al : Patient-specific induced pluripotent stem-cell models for long-QT syndrome. *N Engl J Med* **363** : 1397-1409, 2010
 - 32) Itzhaki I, Maizels L, Huber I, et al : Modelling the long QT syndrome with induced pluripotent stem cells. *Nature* **471** : 225-229, 2011
 - 33) Itzhaki I, Maizels L, Huber I, et al : Modeling of catecholaminergic polymorphic ventricular tachycardia with patient-specific human-induced pluripotent stem cells. *J Am Coll Cardiol* **60** : 990-1000, 2012
 - 34) Carvajal-Vergara X, Sevilla A, D'Souza SL, et al : Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. *Nature* **465** : 808-812, 2010
 - 35) Sun N, Yazawa M, Liu J, et al : Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. *Sci Transl Med* **4** : 130ra47, 2012
 - 36) Raya A, Rodriguez-Piza I, Guenechea G, et al : Disease-corrected haematopoietic progenitors from Fanconi anaemia induced pluripotent stem cells. *Nature* **460** : 53-59, 2009
 - 37) Muller LU, Milsom MD, Harris CE, et al : Overcoming reprogramming resistance of Fanconi anemia cells. *Blood* **119** : 5449-5457, 2012
 - 38) Wang Y, Jiang Y, Liu S, et al : Generation of induced pluripotent stem cells from human beta-thalassemia fibroblast cells. *Cell Res* **19** : 1120-1123, 2009
 - 39) Wang Y, Zheng CG, Jiang Y, et al : Genetic correction of beta-thalassemia patient-specific iPS cells and its use in improving hemoglobin production in irradiated SCID mice. *Cell Res* **22** : 637-648, 2012
 - 40) Papapetrou EP, Lee G, Malani N, et al : Genomic safe harbors permit high beta-globin transgene expression in thalassemia induced pluripotent stem cells. *Nat Biotechnol* **29** : 73-78, 2011
 - 41) Sebastiano V, Maeder ML, Angstman JF, et al : In situ genetic correction of the sickle cell anemia mutation in human induced pluripotent stem cells using engineered zinc finger nucleases. *Stem Cells* **29** : 1717-1726, 2011
 - 42) Zou J, Mali P, Huang X, et al : Site-specific gene correction of a point mutation in human iPS cells derived from an adult patient with sickle cell disease. *Blood* **118** : 4599-4608, 2011
 - 43) Mali P, Ye Z, Hommond HH, et al : Improved efficiency and pace of generating induced pluripotent stem cells from human adult and fetal fibroblasts. *Stem Cells* **26** : 1998-2005, 2008
 - 44) Jiang Y, Cowley SA, Siler U, et al : Derivation and functional analysis of patient-specific induced pluripotent stem cells as an in vitro model of chronic granulomatous disease. *Stem Cells* **30** : 599-611, 2012
 - 45) Zou J, Sweeney CL, Chou BK, et al : Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells : functional correction by zinc finger nuclease-mediated safe harbor targeting. *Blood* **117** : 5561-5572, 2011
 - 46) Hu K, Yu J, Suknuntha K, et al : Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells. *Blood* **117** : e109-e119, 2011
 - 47) Carette JE, Pruszk J, Varadarajan M, et al : Generation of iPSCs from cultured human

- malignant cells. *Blood* **115** : 4039-4042, 2010
- 48) Kumano K, Arai S, Hosoi M, et al : Generation of induced pluripotent stem cells from primary chronic myelogenous leukemia patient samples. *Blood* **119** : 6234-6242, 2012
- 49) Hanna J, Markoulaki S, Schorderet P, et al : Direct reprogramming of terminally differentiated mature B lymphocytes to pluripotency. *Cell* **133** : 250-264, 2008
- 50) Saito M, Nishikomori R, Kambe N, et al : Disease-associated CIAS1 mutations induce monocyte death, revealing low-level mosaicism in mutation-negative cryopyrin-associated periodic syndrome patients. *Blood* **111** : 2132-2141, 2008
- 51) Saito M, Fujisawa A, Nishikomori R, et al : Somatic mosaicism of CIAS1 in a patient with chronic infantile neurologic, cutaneous, articular syndrome. *Arthritis Rheum* **52** : 3579-3585, 2005
- 52) Lee G, Ramirez CN, Kim H, et al : Large-scale screening using familial dysautonomia induced pluripotent stem cells identifies compounds that rescue IKBKAP expression. *Nat Biotechnol*, advanced online publication
- 53) Lee G, Papapetrou EP, Kim H et al : Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. *Nature* **461** : 402-406, 2009
- 54) Gore A, Li Z, Fung HL, et al : Somatic coding mutations in human induced pluripotent stem cells. *Nature* **471** : 63-67, 2011
- 55) Kim K, Doi A, Wen B, et al : Epigenetic memory in induced pluripotent stem cells. *Nature* **467** : 285-290, 2010
- 56) Marchetto MC, Carron C, Acab A, et al : A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. *Cell* **143** : 527-539, 2010
- 57) Mekhoubad S, Bock C, de Boer AS, et al : Erosion of dosage compensation impacts human iPSC disease modeling. *Cell Stem Cell* **10** : 595-609, 2012
- 58) Tomoda K, Takahashi K, Leung K, et al : Derivation conditions impact X-inactivation status in female human induced pluripotent stem cells. *Cell Stem Cell* **11** : 91-99, 2012
- 59) Aizawa E, Hirabayashi Y, Iwanaga Y, et al : Efficient and accurate homologous recombination in hESCs and hiPSCs using helper-dependent adenoviral vectors. *Mol Ther* **20** : 424-431, 2012
- 60) Hockemeyer D, Soldner F, Beard C, et al : Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases. *Nat Biotechnol* **27** : 851-857, 2009
- 61) Hockemeyer D, Wang H, Kiani S, et al : Genetic engineering of human pluripotent cells using TALE nucleases. *Nat Biotechnol* **29** : 731-734, 2011
- 62) Ding Q, Lee YK, Schaefer EA, et al : A TALEN Genome-Editing System for Generating Human Stem Cell-Based Disease Models. *Cell Stem Cell* 2012 Dec 12. pii : S1934-5909(12)00645-5. doi : 10.1016/j.stem.2012.11.011 (Epub ahead of print)
- 63) Soldner F, Laganier J, Cheng AW, et al : Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. *Cell* **146** : 318-331, 2011

TECHNOLOGY REPORT

Optimization of Slow Cooling Cryopreservation for Human Pluripotent Stem Cells

Takamichi Miyazaki,¹ Norio Nakatsuji,^{2,3} and Hirofumi Suemori^{1*}¹Department of Embryonic Stem Cell Research, Institute for Frontier Medical Sciences, Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan²Institute for Integrated Cell-Material Sciences (WPI-iCeMS), Kyoto University, Ushinomiya-cho, Yoshida, Sakyo-ku, Kyoto 606-8501, Japan³Department of Development and Differentiation, Institution for Frontier Medical Sciences, Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, 606-8507, Japan

Received 25 June 2013; Revised 25 October 2013; Accepted 8 November 2013

Summary: Human pluripotent stem cells (hPSCs) have the potential for unlimited expansion and differentiation into cell types of all three germ layers. Cryopreservation is a key process for successful application of hPSCs. However, the current conventional method leads to poor recovery of hPSCs after thawing. Here, we demonstrate a highly efficient recovery method for hPSC cryopreservation by slow freezing and single-cell dissociation. After confirming hPSC survivability after freeze-thawing, we found that hPSCs that were freeze-thawed as colonies showed markedly decreased survival, whereas freeze-thawed single hPSCs retained the majority of their viability. These observations indicated that hPSCs should be cryopreserved as single cells. Freeze-thawed single hPSCs efficiently adhered and survived in the absence of a ROCK inhibitor by optimization of the seeding density. The high recovery rate enabled conventional colony passaging for subculture within 3 days post-thawing. The improved method was also adapted to a xeno-free culture system. Moreover, the cell recovery postcryopreservation was highly supported by coating culture surfaces with human laminin-521 that promotes adhesion of dissociated single hPSCs. This simplified but highly efficient cryopreservation method allows easy handling of cells and bulk storage of high-quality hPSCs. *genesis* 52:49–55, 2014. © 2013 Wiley Periodicals, Inc.

Key words: ectoderm; tissue endoderm; tissue mesoderm; tissue other; tissue germ layer; process; early development; single cell dissociation; slow freezing

Human pluripotent stem cells (hPSCs), including human embryonic stem cells (hESCs) and human induced

pluripotent stem cells (hiPSCs), have an infinite proliferative potential and capacity for differentiation into all cells of the three germ layers. For successful application of hPSCs in transplantation therapy or drug discovery, it is necessary to prepare large numbers of hPSCs with various genetic backgrounds (Serra *et al.*, 2012). There are several approaches to improve the yield of hPSCs, but cryopreservation is a key operation because it enables long-term preservation and easy transportation of cells. Currently, hPSCs are cryopreserved by vitrification or slow cooling (Heng *et al.*, 2005; Reubinoff *et al.*, 2001). Vitrification involves flash cooling directly in liquid nitrogen, and some studies have recovered 20–90% of undifferentiated hPSC colonies postcryopreservation (Li *et al.*, 2010; Suemori *et al.*, 2006). However, vitrification requires skilled manipulation and strict temperature control during storage and transportation, because of the small volumes of cryoprotectant used, making it impractical for large-scale storage of hPSCs. In contrast, conventional slow cooling controls the cooling rate at 1°C/min in freezing medium that

Additional Supporting Information may be found in the online version of this article.

* Correspondence to: Hirofumi Suemori, Department of Embryonic Stem Cell Research, Institute for Frontier Medical Sciences, Kyoto University, 53 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606-8507, Japan. E-mail: hsuemori@frontier.kyoto-u.ac.jp

Contract grant sponsors: New Energy and Industrial Technology Development Organization (NEDO), Japan; Ministry of Health, Labour and Welfare, Japan

Published online 19 November 2013 in
Wiley Online Library (wileyonlinelibrary.com).
DOI: 10.1002/dvg.22725

typically contains 10% dimethylsulfoxide (DMSO). The slow cooling method is widely used because it is applicable to various cell types including mouse embryonic stem cells. However, for cryopreservation of hPSCs, the slow cooling method results in less than 10% survivability (Wagh *et al.*, 2011). Nevertheless, for bulk storage and easy handling, slow cooling is desirable for cryopreservation of hPSCs. In this study, we aimed to optimize the slow cooling method for hPSC cryopreservation.

Cryopreservation involves a series of processes including cell detachment, freezing, storage, thawing, and reseeded. During these processes, hPSCs may suffer necrotic cell death from cell detachment to thawing because of physical damage, and apoptotic cell death at reseeded because of adhesion failure. Therefore, hPSC survivability should be verified at each step. However, previous studies have reported different timings for their analyses, various methods of measurement, and counting either colonies or individual cells (Li and Ma, 2012). In particular, counting of colonies postseeding, although it has been often performed, is inaccurate because it leads to overestimation because of an increase of colony formation caused by fragmentation of the original colonies during freeze-thaw processes. For correct evaluation of the survival efficiency, in this study, we counted individual hPSCs in a stepwise manner.

To evaluate the effect of different methods of cell detachment from culture vessels, we first compared

cell survival after conventional colony dissociation or single-cell dissociation. While the viability of cells detached by conventional colony dissociation before freezing were approximately halved (42.3–59.4% survival), the majority of hPSCs cryopreserved under a colony state were already dead immediately after freeze-thawing (15.5–32.5% survival) (Fig. 1a, c, e–h). Although the conventional dissociation method maintains the colony state to prevent apoptosis caused by failure to adhere at reseeded, hPSCs had already died by necrosis before attachment. This observation suggests that it is necessary to avoid cell death mainly caused by physical damage during cell dissociation and freeze-thawing processes. Next, we performed freeze-thawing of dissociated hPSCs. The majority of dissociated hPSCs showed higher viability before cryopreservation (68.1–77.7% survival). More importantly, single hPSCs were still alive just after thawing (59.7–66.1% survival), corresponding to 80–90% viability just after dissociation (Fig. 1b, d, e–h).

Although we found that single-cell dissociation of hPSCs is advantageous for freeze-thawing, it is necessary to avoid apoptotic cell death caused by dissociation (Amit *et al.*, 2000). Because we previously showed that the seeding density significantly affects the survivability of single hPSCs (Miyazaki *et al.*, 2012), we next assessed the effect of seeding density on the viability of freeze-thawed single hPSCs. The number of hPSCs




FIG. 1. hPSC survivability is influenced by the cellular state during cryopreservation. (a–d) Estimation of cellular state-dependent hPSC survivability by trypan blue exclusion. Representative bright field images of colony-dissociated H9 hESCs before (a) and after (b) cryopreservation and single dissociated H9 hESCs before (c) and after (d) cryopreservation. (e–h) Flow cytometric analysis of cellular state-dependent hPSC survivability during cryopreservation by fluorescent dye influx. e: H9 hESCs; f: 253G1 hiPSCs; g: KhES-1 hESCs; h: iPS(IMR90)-1 hiPSCs. Error bars indicate the standard deviation (SD) of three experiments. Scale bars: 200 μm.

attached to the substrate gradually decreases to the minimum at 12 h postseeding (Chen *et al.*, 2010). To evaluate survival correctly, we measured the viability of freeze-thawed single hPSCs at 12 h postseeding. On Matrigel in mTeSR1 medium, freeze-thawed single H9 hESCs seeded at 3×10^5 cells/cm² showed maximum survivability ($36.2 \pm 6.0\%$ survival) (Fig. 2a, c), indicating the optimal condition for recovery of cryopreserved hPSCs. It is well known that administration of a Rho-associated protein kinase (ROCK) inhibitor dramatically improves the survival of single hPSCs (Watanabe *et al.*, 2007). However, ROCK inhibitor treatment did not significantly improve the survival of single hPSCs seeded at the optimal density (Fig. 2b). An effect of the ROCK inhibitor was only observed when single hPSCs were seeded at a lower cell density. These results indicate that a ROCK inhibitor is unnecessary for the optimized seeding density, whereas it should be administrated when single hPSCs are seeded at a lower seeding

density. For stable survival of hPSCs, cell-cell contact is a key element (Chen *et al.*, 2010). Therefore, the seeding density of single hPSCs should be as high as possible for rapid formation of cell-cell contacts. However, seeding at very high densities leads to less efficient survival because of depletion of the adhesion surface. It is therefore important for freeze-thawed single hPSCs to be seeded at an appropriate density.

After adherence of single hPSCs, the majority of single hPSCs immediately formed cell-cell contacts as small clusters (Fig. 2c). By 3 days post-thawing, the cells had grown as colonies and reached confluency for passaging (Fig. 2d). Immediately after freeze-thawing, flow cytometric analysis showed that hPSCs remained in an undifferentiated state and maintained the undifferentiated status following subculture (Fig. 3a). After the first passage, hPSCs grew as colonies (Fig. 3b) and sustained an undifferentiated state (Fig. 3a, c) and potential for differentiation (Fig. 3c) without karyotypic abnormalities




FIG. 2. Recovery of freeze-thawed single hPSCs. (a) Seeding density-dependent adhesion of freeze-thawed single H9 hESCs at 12 h postseeding. Cell viability is expressed as the ratio of the attached cell number to live H9 hESCs at seeding. Data represent the means \pm SD of three freeze-thawing experiments of one cryopreserved batch of cells. (b) Effect of the ROCK inhibitor Y-27632 on adhesion of freeze-thawed single H9 hESCs at 12 h postseeding. Error bars indicate the SD. of three experiments. $**P < 0.05$; ns, not significant, two-tailed Student's *t*-test. (c, d) Phase contrast images of freeze-thawed single H9 hESCs at 12 h (c) and 3 days (d) postseeding at 3×10^5 cells/cm². Scale bars: 200 μ m.




FIG. 3. Characterization of freeze-thawed hPSCs. (a) Flow cytometric analysis of undifferentiated markers before cryopreservation (I), at 3 days postseeding (II), and at subculture (III). (b) Phase contrast image of H9 hESCs at subculture. (c) Reverse transcription-PCR analysis of differentiation marker gene expression in embryoid bodies. Total RNA was extracted from day 14 embryoid bodies generated from cells after subculture. undiff. indicates cells at subculture. (d) G-banding analysis of H9 hESCs after subculture. Data for subcultured cells were obtained at two passages after freeze-thawing. Scale bars: 200 μ m.

(Fig. 3d). Thus, hPSCs can be rapidly and efficiently cryopreserved by slow cooling while maintaining their pluripotent state.

Because hPSCs used for transplantation therapy would be expanded under xeno-free culture conditions, we evaluated xeno-free TeSR2 medium and recombinant human laminin-521 as the culture substrate. Laminin-521 is a laminin isoform used to improve the adhesion of dissociated hPSCs. Freeze-thawed single hPSCs in TeSR2 medium showed high survivability ($86.8 \pm 3.1\%$ survival) immediately after freeze-thawing. Considering the promotion of adhesive by laminin-521, we re-evaluated the seeding density and found that freeze-thawed single hPSCs seeded at 1×10^5 cells/cm² showed maximal survival ($59.7 \pm 15.5\%$ survival for H9 hESCs and $43.2 \pm 11.2\%$ survival for 253G1 iPSCs) (Fig. 4a and Supporting Information Fig. 1a). Moreover, on the laminin-521-coated culture surface, a higher number of single hPSCs were able to adhere and survive even at a lower seeding density ($36.2 \pm 6.1\%$ survival for H9 hESCs and $32.5 \pm 8.7\%$ for 253G1 iPSCs at 0.25×10^5 cells/cm²). After reseeding, the freeze-thawed hPSCs rapidly formed colonies on laminin-521 (Fig. 4b) and could be passaged within 3 days (Fig. 4c). The freeze-thawed hPSCs maintained their undifferentiated state (Fig. 4d, e, and Supporting Information Fig. 4b), potential for differentiation (Fig. 4e), and a normal karyotype after passaging on laminin-521 in TeSR2 medium (Fig. 4f). Therefore, freeze-thawing of single hPSCs is applicable to xeno-free culture conditions, and

human laminin-521 enhances the survival of single hPSCs after thawing.

In the present study, we obtained a high recovery rate following cryopreservation by optimizing the cellular state during freezing and the seeding density after thawing. These modifications achieved 80–90% survival of hPSCs post-thawing and around 60% survival following subculture on laminin-521, even in the absence of a ROCK inhibitor. hPSCs are delicate cells as compared with other types of cultured cells. Therefore, hPSCs require specific conditions not only for maintenance in culture but also for cryopreservation. Most previous approaches for effective hPSC cryopreservation have focused on development of a cryoprotectant specific for hPSCs (Ha *et al.*, 2005; T'Joene *et al.*, 2012). However, our study demonstrated that a fundamental solution for cryopreservation of hPSCs is their cellular state. It is therefore necessary to consider the cellular state for further investigation of hPSC cryopreservation. Moreover, our examination of the survivability of individual cells in a stepwise manner will contribute to estimation of the precise survival efficiency of hPSC cryopreservation.

It is still unclear why hPSC colonies are susceptible to injury after freeze-thawing. One risk is that hPSC colonies undergo unavoidable physical damage. Because cell scraping and pipetting for cell detachment is usually associated with cell rupture, freeze-thawed colonies of hPSCs may still be damaged following cell detachment. In addition, cell colonies have poor penetration of cryoprotectant. During cryopreservation, cells are




FIG. 4. Cryopreservation of single hPSCs under xeno-free culture conditions. (a) Seeding density-dependent adhesion of freeze-thawed single H9 hESCs on laminin-521 in TeSR2 medium at 12 h postseeding. Cell viability is expressed as the ratio of the attached cell number to live H9 hESCs at seeding. Data represent the means \pm SD of three freeze-thawing experiments of one cryopreserved batch of cells. (b, c) Phase contrast images of freeze-thawed single H9 hESCs at 12 h (b) and 3 days (c) postseeding at 1×10^5 cells/cm². (d) Flow cytometric analysis of undifferentiation markers before cryopreservation (I), at 3 days postseeding (II), and at subculture (III). (e) Reverse transcription-PCR analysis of differentiation marker gene expression in embryoid bodies. Total RNA was extracted from day 14 embryoid bodies generated from cells after subculture. (f) G-banding analysis of H9 hESCs after subculture. Data for subcultured cells were obtained at two passages after freeze-thawing. Scale bars: 200 μ m.

often ruptured by rapid osmotic changes caused by the cryoprotectant (Hunt, 2011). hPSC colonies are tightly connected by cell-cell interactions such as adherence junctions, and their formation generates a heterogeneous cellular state for cryoprotectant penetration. When compared with a complex cellular structure, single cells may be more suitable for cryopreservation in terms of cryoprotectant penetration. In addition, dissociation to single cells may minimize cellular damage at detachment because physical manipulation is unnecessary. Here, we used TrypLE Select as the dissociation solution, but other dissociation solutions used for single cell passaging, such as accutase and trypsin, would provide similar results.

In conclusion, our method enables highly efficient slow cooling of hPSCs. The cellular manipulation is simple and very similar to commonly used techniques for culturing most mammalian cell lines. Furthermore, our method is suitable for large-scale cryopreservation of pluripotent stem cell lines and machine-aided automation.

METHODS

Matrix Coating

Six-well flat-bottomed plates (BD Falcon, 353046) and 12-well flat-bottomed plates (BD Falcon, 353043)

were coated with Matrigel (BD Biosciences, 354230) at 25 μ g/cm² or laminin-521 (Bio Lamina, BLA-LN521-02) at 3 μ g/cm² for 3 h at room temperature (RT) just prior to use. Matrigel and laminin-521 were diluted in DMEM/F12 or D-PBS, respectively.

Maintenance and Passaging of hPSCs

hESC lines, H9 and KhES-1, and hiPSC lines, iPS(IMR90) clone 1, and 253G1 were maintained on mitomycin C-treated mouse embryonic fibroblasts as described previously (Suemori *et al.*, 2006). hPSCs were transferred onto Matrigel-coated culture vessels in mTeSR1 medium (StemCell Technologies, ST-05850) or laminin-521-coated culture vessels in TeSR2 medium (StemCell Technologies, ST-05860) following the manufacturer's instructions.

Subculture was performed by colony dissociation as follows. Semi-confluent hPSCs were incubated with 2 mg/ml dispase in DMEM/F12 at 37°C for 3 min, and then rinsed twice with DMEM/F12. After addition of culture medium, weakly adherent colonies were detached using a cell scraper. The cells were collected and centrifuged at 200g for 3 min at 4°C. Small colonies were passaged onto fresh matrix-coated culture vessels at a ratio of 1:4. The cells were cultured at 37°C with 3% CO₂ in a humidified incubator. Medium changes were performed daily.